This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Alecensa®▼(alectinib)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼ (pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozlytrek®▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Haematology
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • Evrysdi®▼ (risdiplam)
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib) Great Britain
      • ALECENSA® (alectinib) Northern Ireland
      • Avastin® (bevacizumab) [Great Britain]
      • Avastin (bevacizumab) [Northern Ireland]
      • Evrysdi®▼(risdiplam)
      • GAZYVARO® (obinutuzumab) Great Britain
      • GAZYVARO® (obinutuzumab) Northern Ireland
      • HEMLIBRA®▼(emicizumab) Great Britain
      • HEMLIBRA®▼(emicizumab) Northern Ireland
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab) GB
      • OCREVUS®▼ (ocrelizumab) NI
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin) Great Britain
      • Polivy®▼(polatuzumab vedotin) Northern Ireland
      • Rozlytrek® ▼(entrectinib)
      • TECENTRIQ®▼ (atezolizumab) Great Britain
      • Tecentriq® (atezolizumab) Northern Ireland
    • Adverse Event Reporting
      Adverse Event Reporting Overview
    • Home
    • Roche Medicines
      • Oncology
        • Alecensa®▼(alectinib)
        • Kadcyla® (trastuzumab emtansine)
        • PERJETA® (pertuzumab)
        • PHESGO®▼ (pertuzumab/trastuzumab)
        • TECENTRIQ®▼ (atezolizumab)
        • Rozlytrek®▼(entrectinib)
      • Neuroscience
        • OCREVUS®▼ (ocrelizumab)
      • Haematology
        • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
        • Evrysdi®▼ (risdiplam)
        • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      • Oncology
        • Breast Cancer
      • Haematology
        • Haematology
      • Neuroscience
        • Neuroscience
    • Congress and Meetings
    • HCP Materials
    • FAQs
    • Prescribing Information
      • Find out more about:
        • ALECENSA®▼(alectinib) Great Britain
        • ALECENSA® (alectinib) Northern Ireland
        • Avastin® (bevacizumab) [Great Britain]
        • Avastin (bevacizumab) [Northern Ireland]
        • Evrysdi®▼(risdiplam)
        • GAZYVARO® (obinutuzumab) Great Britain
        • GAZYVARO® (obinutuzumab) Northern Ireland
        • HEMLIBRA®▼(emicizumab) Great Britain
        • HEMLIBRA®▼(emicizumab) Northern Ireland
        • Herceptin® (trastuzumab) IV
        • Herceptin® (trastuzumab) SC
        • Kadcyla® (trastuzumab emtansine)
        • OCREVUS®▼ (ocrelizumab) GB
        • OCREVUS®▼ (ocrelizumab) NI
        • Perjeta® (pertuzumab)
        • Phesgo®▼(pertuzumab/trastuzumab)
        • Polivy®▼(polatuzumab vedotin) Great Britain
        • Polivy®▼(polatuzumab vedotin) Northern Ireland
        • Rozlytrek® ▼(entrectinib)
        • TECENTRIQ®▼ (atezolizumab) Great Britain
        • Tecentriq® (atezolizumab) Northern Ireland
    • Adverse Event Reporting
    • Sign in
    • Logout
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    • Tecentriq-HCC

      Read more

    • TECENTRIQ®▼ (atezolizumab)
    • HCC
      • Efficacy
      • QoL
      • Safety
      • MOA
      • Study design
    • NSCLC
      • Efficacy
      • Safety
      • How to Use
    • eNSCLC
    • More
      • HCC
      • NSCLC
      • eNSCLC

    You are here:

    1. Roche Medicines
    2. Oncology
    3. TECENTRIQ®▼ (atezolizumab)
    4. HCC

    ▼Tecentriq is subject to additional monitoring in Great Britain. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. In Northern Ireland, a black triangle is not required for Tecentriq and it is not subject to additional monitoring.

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.

    As Tecentriq is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

    Prescribing Information

    TECENTRIQ®▼(atezolizumab) Great Britain
    TECENTRIQ® (atezolizumab) Northern Ireland
    Avastin (bevacizumab) Great Britain
    Avastin (bevacizumab) Northern Ireland

    Adverse event reporting and additional monitoring

    You’ve waited over 10 years for a superior treatment to sorafenib1

    Now you can offer your adult patients with advanced or unresectable HCC TECENTRIQ (atezolizumab) + Avastin (bevacizumab), a first-line systemic therapy2,3 that gives them the chance of:

    Longer OS and PFS vs sorafenib4

    •  Median OS: NE vs 13.2 (95% CI: 10.4–NE) months (HR: 0.58, 95% CI: 0.42–0.79, p<0.001*)
    •  Median PFS: 6.8 (95% CI: 5.7–8.3) vs 4.3 (95% CI: 4.0–5.6) months (HR: 0.59, 95% CI: 0.47–0.76, p<0.001*)

    See the OS and PFS data

    Greater and more sustained tumour shrinkage vs sorafenib4

    •  ORR: 27.3% (95% CI: 22.5–32.5) vs 11.9% (95% CI: 7.4–18.0); p<0.001*
    •  >6-month DoR in responders: 87.6% vs 59.1%

    See the ORR data

    Longer maintenance of QoL vs sorafenib4

    •  Median time to QoL deterioration: 11.2 (95% CI: 6.0–NE) vs 3.6 (95% CI: 3.0–7.0) months (HR: 0.63; 95% CI: 0.46– 0.85*)

    See the QoL data

    Longer treatment duration vs sorafenib with a generally manageable safety profile4

    •  Median DoT (months): 7.4 for TECENTRIQ, 6.9 for Avastin, 2.8 for sorafenib

    See the safety profile

    *Stratified by geographic region (Asia excluding Japan vs the rest of the world), baseline alpha-fetoprotein (<400 ng/mL vs ≥400 ng/mL) and macrovascular invasion, extrahepatic spread, or both (yes vs no).

    Recommended by ESMO5

     

    • TECENTRIQ + Avastin has been included in ESMO clinical practice guidelines as a consideration since January 2020 (evidence level III, B)

    TECENTRIQ + Avastin was upgraded by ESMO in June 2020 to a first-line standard of care for HCC patients at BCLC stage C† (evidence level I, A)

    †Portal invasion, extrahepatic spread, preserved liver function, ECOG PS 0–2 and Child-Pugh A.

    More
    More

    BCLC, Barcelona clinic liver cancer; CI, confidence interval; DoR, duration of response; DoT, duration of treatment; ECOG PS, Eastern Cooperative Oncology Group performance status; ESMO, European Society for Medical Oncology; HCC, hepatocellular carcinoma; HR, hazard ratio; MOA, mode of action; NE, non-evaluable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; QoL, quality of life.

    References:

    1. Rimassa L et al. Liver Cancer 2019;8:427–446.
    2. TECENTRIQ GB Summary of Product Characteristics.
    3. TECENTRIQ NI Summary of Product Characteristics.
    4. Finn RS et al. N Engl J Med 2020;382:1894–1905.
    5. ESMO. HCC: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Available at https://www.esmo.org/guidelines gastrointestinal-cancers/hepatocellular-carcinoma/eupdate-hepatocellular-carcinoma-algorithm (accessed April 2022).

     




    M-GB-00006952

    Date of preparation: April 2022.

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2022 Roche Products Limited
    • 01.07.2022
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    This is a promotional website intended for UK healthcare professionals, designed, built and funded by Roche Products Ltd. This website is intended to be viewed on a desktop/laptop. M-GB-00008047 Date of Preparation June 2022.